KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) FCF Margin: 2020-2025

Historic FCF Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -2,272.52%.

  • Recursion Pharmaceuticals' FCF Margin fell 202796.00% to -2,272.52% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,024.72%, marking a year-over-year decrease of 51495.00%. This contributed to the annual value of -633.71% for FY2024, which is 3872.00% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' FCF Margin is -2,272.52%, which was down 449.02% from -413.92% recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' FCF Margin peaked at 1,369.70% during Q1 2022, and registered a low of -2,590.68% during Q4 2021.
  • In the last 3 years, Recursion Pharmaceuticals' FCF Margin had a median value of -699.15% in 2023 and averaged -951.66%.
  • Examining YoY changes over the last 5 years, Recursion Pharmaceuticals' FCF Margin showed a top increase of 2,887,673bps in 2021 and a maximum decrease of 277,225bps in 2021.
  • Recursion Pharmaceuticals' FCF Margin (Quarterly) stood at -2,590.68% in 2021, then surged by 220,514bps to -385.54% in 2022, then slumped by 31,360bps to -699.15% in 2023, then plummeted by 186,856bps to -2,567.71% in 2024, then crashed by 202,796bps to -2,272.52% in 2025.
  • Its last three reported values are -2,272.52% in Q3 2025, -413.92% for Q2 2025, and -907.35% during Q1 2025.